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Purpose: Diabetes is the leading cause of end-stage renal failure. The present study 
was undertaken to characterize the effects of Corni Fructus on diabetic nephropathy 
in streptozotocin-induced diabetic rats and their mechanisms. Materials and Meth-
ods: Streptozotocin-diabetic rats were orally administrated with Corni Fructus at a 
dose of 100, 200 or 400 mg/kg body mass for 40 days. Results: Corni Fructus-treat-
ed diabetic rats showed significant decreases of blood glucose, urinary protein levels 
and water consumption. Corni Fructus also reduced serum total cholesterol, total tri-
glyceride and low-density lipoprotein cholesterol levels, and showed a tendency of 
enhancing high-density lipoprotein cholesterol level. Levels of serum albumin and 
creatinine in diabetic rats were also significantly reduced by Corni Fructus adminis-
tration at a dose of 200 and 400 mg/kg body mass compared with non-treated diabetic 
rats. Corni Fructus increased catalase (CAT), superoxide dismutase (SOD) and gluta-
thione peroxidose (GSH-px) activities in the kidneys of diabetic rats. Furthermore, 
Corni Fructus treatment enhanced renal peroxisome proliferator-activated receptor-γ 
(PPARγ) expression in diabetic rats. Conclusion: These results demonstrated that 
Corni Fructus may have the potential to protect the animals from diabetic nephropa-
thy by amelioration of oxidative stress and stimulation of PPARγ expression.
Key Words:    Corni Fructus (Cornus officinalis Sieb. et Zucc.), diabetic nephropa-
thy, peroxisome proliferator-activated receptor-γ (PPARγ), antioxi-
dant enzymes 
INTRODUCTION
Diabetes mellitus, a common metabolic disease characterized by elevated blood 
glucose, has been linked to diabetic complications such as hyperlipidemia and reti-
nopathy. In particular, there is an increased risk of diabetes in several types of kid-
ney disease, and the predominant cause of end-stage renal disease in this disorder is 
diabetic nephropathy.1 Furthermore, there is considerable evidence to indicate that 
oxidative stress plays a role in the pathogenesis of diabetic nephropathy.2 Oxygen 
free radicals exert their cytotoxic effects on membrane phospholipids resulting in 
the formation of malondialdehyde (MDA). In addition, diabetes is usually accom-
panied with an increase in lipid peroxidation, alteration of the glutathione redox Dawei Gao, et al.
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Chemical Co., ursolic acid standards from Yousi Biotech-
nology Inc. (Shanghai, China), streptozotocin from Sigma 
Chemicals Co. (St. Louis, MO, USA), glucose analyzer 
(GT-1640) and strips from Arkray Inc. (Kyoto, Japan), and 
Corni Fructus from Chang Hai Traditional Chinese Medi-
cine Ltd. (Qinhuangdao, China). The identity of Corni Fruc-
tus was verified by a botanist.
Extraction and identification of Corni Fructus
Powdered Corni Fructus was initially soaked in 10 vol-
umes of 70% ethanol for 2 hours and then extracted with 
ultrasound for 30 minutes. The supernatant was concentrat-
ed by a rotary evaporator and vacuum dried. The powdered 
extract was resuspended in water and resolves by a column 
chromatography, using macroporous resin (AB-8) column 
successively eluted with dH2O, 50%, 75% and anhydrous 
ethanol. The anhydrous ethanol phase was collected, dried, 
and then examined by thin-layer chromatogram (TLC) 
analysis. 
Induction of diabetes in rats
Male Wistar rats, weighing 220-240 g, were provided by 
the Zoology Department of the Beijing Institute of Tradi-
tional Medical and Pharmaceutical Sciences. The rats were 
fed a standard rat chow diet and had free access to water. 
Experimental diabetes was induced by a single intraperito-
neal injection of streptozotocin at a dose of 60 mg/kg body 
mass (using a freshly prepared solution in 0.1 M citrate buf-
fer, pH 4.5) to the animals who fasted overnight while con-
trol rats were injected with citrate buffer alone. Blood sam-
ples were obtained from the tail vein after an overnight fast 
at 72 hour post-injection. Rats with fasting blood glucose 
levels in the range of 16.7 to 25 mM were defined as dia-
betic model rats.14 All animal procedures were performed 
according to the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals.
Experimental design
Group I consisted of 8 healthy rats and received 0.5% car-
boxymethylcellulose (CMC) solution. Streptozotocin-in-
duced diabetic rats were divided into four groups of 8 ani-
mals each (Groups II-V). Group II served as a diabetic 
control and received 0.5% CMC solution, while Groups III, 
IV, and V received 100, 200 and 400 mg/kg body mass of 
Corni Fructus extract dissolved in 0.5% CMC solution: the 
rats were administered intragastrically once daily for 40 
days. Water intake and body weight were determined every 
state, a decrease in the content of individual natural antioxi-
dants, and decreased induction of antioxidant enzymes.3 
Peroxisome proliferator-activated receptor-γ (PPARγ) is a 
member of the nuclear hormone receptor superfamily of li-
gand-activated transcription factors. It plays important roles 
in maintaining glucose, insulin sensitivity, lipid homeostasis 
and cell cycle regulation.4 PPARγ agonist ligands can atten-
uate the expression or activity of nicotinamide adenine dinu-
cleotide oxidase, which is now considered to be a key patho-
genic mediator of injury in the diabetic kidney. Therefore, 
PPARγ activators are used widely in the treatment of type 2 
diabetes, and they improve the sensitivity of insulin recep-
tors. Stimulation of PPARγ may trigger its association with 
the corepressor NCoR, thereby preventing dissociation of 
NCoR from the iNOS promoter and subsequent gene ac-
tion.5 Troglitazone was the first PPARγ agonist to be used in 
the clinic. However, this compound was withdrawn because 
marked hepatotoxicity adverse effects were observed. Rosi-
glitazone, another PPARγ agonist, increases the risk of bone 
fractures, weight gain and edema.6 Modern drugs, including 
insulin and other oral hypoglycemic agents such as bigua-
nides, sulphonylureas and alpha-glucosidase inhibitors, can 
control blood glucose level as long as they are administered 
regularly, however, they may also produce a number of un-
desirable side-effects.7 
All of these observations have raised an enthusiasm in 
the development of new PPARγ agonists devoid of side-ef-
fects. At present, medical plants play a major role in the in-
troduction of new therapeutic agents and have received much 
attention as the sources of biologically active substances 
because of its nontoxic and non side-effect properties.8,9 
Corni Fructus (Cornus officinalis SIEB. et Zucc.) has at-
tracted much interest due to its various biological activities, 
including immunological regulation, blood glucose reduc-
tion and antimicrobial activity.10-12 We earlier optimized the 
extraction method for Corni Fructus and evaluated its anti-
diabetic properties in alloxan-induced diabetic mice.13 In 
the present study, we investigated the effects of Corni Fruc-
tus on antioxidation, PPARγ expression and renal function 
in streptozotocin-induced diabetic rats in order to study its 
renal protective effects and hypoglycemic mechanisms.
MATERIALS AND METHODS
　　　
Chemicals and plant material
Macroporous resin was purchased from Nan Kai University Antidiabetic Effects of Corni Fructus
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oxide dismutase (SOD) using commercial kits according to 
the manufacturer’s instructions (Nanjing Jiancheng Bioengi-
neering Co., Nanjing, China). 
Westhern blotting
One quarter of the kidney tissues from each rat was homog-
enized in ice-cold lysis buffer containing 2% sodium dodec-
ylsulfate (SDS), 100 mM proteinase cocktail inhibitor, 1 
mM phenylmethylsulfonylfluoride, 1 mM dithiothreitol, and 
5 mM ethylenediaminetetraacetic acid in 50 mM Tris-buff-
ered saline (TBS, 50 mM Tris-HCl, pH 7.4). After centrifu-
gation (12500×g, 5 minutes, 4°C), the supernatants were 
collected. Samples (100 µg protein) were boiled for 3 min-
utes and subjected to 10% SDS-PAGE. After electrophore-
sis, proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (invitrogen). The blots were incubated 
in blocking buffer (TBST, 5% skim milk in TBS containing 
0.1% Tween-20) for 1 hour at room temperature and then 
probed overnight with a 1:1000 dilution of goat polyclonal 
anti-PPARγ (Santa Cruz, CA, USA) at 4°C. The blots were 
washed three times with TBST for 10 minutes and reacted 
with goat anti-rat horseradish peroxidase (HRP)-conjugated 
antibody (1:5000 dilution; Sigma, St. Louis, MO, USA) for 
1 hour at room temperature. The immunoreactive bands 
were visualized using enhanced chemiluminescence (ECL 
Kit; Millipore, Billerica, MA, USA). The membranes were 
exposed to X-ray films, and band intensities were quantified 
using Scion Image.
Reverse transcriptase polymerase chain reaction 
(RT-PCR)
Total mRNA from one quarter of the kidney tissues from each 
rat was extracted with Trizol reagent (invitrogen). Relative 
levels of specific mRNAs were assessed by reverse transcrip-
tase polymerase chain reaction (RT-PCR). Single-stranded 
cDNA was synthesized from 1 µg of total RNA using avian 
myeloblastosis virus (AMV) reverse transcriptase in a total re-
action volume of 20 µL (Promega, Madison, WI, USA). The 
reverse transcription program was 25°C for 10 minutes, 42°C 
for 50 minutes, and then 70°C for 15 minutes. cDNA was 
synthesized with Taq DNA Polymerase (Promega, Madison, 
WI, USA). The genes examined were PPARγ (GenBank Ac-
cession No. NM 013124: 265 bp; forward primer: 5’- 
ACTCCCATTCCTTTGACATC-3’, reverse primer: 5’- 
TCCCCACAGACTCGGCACTC-3’)16, and β-actin (228 bp; 
sense primer: 5’-AGCCATGTACGTAGCCATCC-3’ and an-
tisense primer: 5’-CTCTCAGCTGTGGTGGTGAA-3’). 
2 days, while blood glucose levels were measured at 10 day 
intervals using the glucose oxidase method to ascertain dia-
betic status of each group.15  
Oral glucose tolerance test (OGTT)
On day 1 after overnight fasting with free access to water, 
the rats were administered with Corni Fructus extract dis-
solved in a solution of 0.5% CMC by oral gavage at the fol-
lowing doses: 100 mg/kg body mass (Group III), 200 mg/kg 
body mass (Group IV), and 400 mg/kg body mass (Group 
V), or with the same volume of 0.5% CMC solution alone 
(Groups I and II). Tail blood samples were drawn from each 
rat, and a glucose (1.0 g glucose/kg body mass) solution was 
given by oral gavage to all experimental rats 30 minutes af-
ter Corni Fructus administration. A baseline (0 minute) 
blood sample was taken from the tail vein in normal control 
and experimental rats, and the blood samples were then col-
lected at 30, 60, 90, and 120 minute intervals following glu-
cose administration. Blood plasma glucose levels were mea-
sured at various time points using the glucose oxidase 
method. 
In vivo biochemical assays
On day 40, blood samples were collected from the eyes of 
fasted experimental rats under ether anaesthesia, left at 
room temperature for 2 hours and then centrifuged at 
1500×g for 15 minutes to prepare serum. Serum was used 
to determine the levels of total cholesterol (TC), total tri-
glyceride (TG), low-density lipoprotein cholesterol (LDL-
C) and high-density lipoprotein cholesterol (HDL-C) levels 
following the instructions of the manufacturer (Nanjing Ji-
ancheng Bioengineering Co., Nanjing, China). Serum sam-
ples were also used for measuring creatinine and blood urea 
nitrogen (BUN). Twenty-four hour urinary protein concen-
trations were determined by the Bradford method, by using 
commercial kits (Nanjing Jiancheng biomedical engineer-
ing Co. Ltd.). 
Measurement of MDA, SOD, CAT and GSH-px levels  
All animals were sacrificed on day 40 by cervical disloca-
tion under ether anesthesia and kidney tissues of each ani-
mal were rapidly excised, weighed and washed twice with   
cold phosphate buffer solution (PBS). One quarter of the 
kidney tissue from each rat was weighed, homogenized with 
Tris-HCl (pH 7.4), and centrifuged (1500×g, 10 minutes, 
4°C). Supernatants were used immediately to assay MDA, 
glutathione peroxidase (GSH-px), catalase (CAT) and super-Dawei Gao, et al.
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Fructus were analyzed using one-way ANOVA, followed by 
the Scheffe test. Results were considered significantly differ-
ent at the level of p<0.05.
RESULTS
 
Characterization of Corni Fructus extract
The extract was analyzed using TLC by comparing the col-
or and retardation factor (Rf) value with ursolic acid stan-
dards. The sample turned purple and had the same Rf value 
as the ursolic acid standards, showing that the main active 
ingredient in the Corni Fructus extract prepared above was 
ursolic acid. The sample also contained a little organic acid 
and glycoside. 
Effects of Corni Fructus on rat body weight
As shown in Table 1, the body weight of Group I increased 
consistently from 233.38 g to 325.63 g during the forty-day 
experiment, while the diabetic group showed a significant 
decrease in body weight from 233.38 g to 207.88 g. How-
ever, the body weight of Corni Fructus-treated groups in-
creased significantly, especially in Groups IV and V, com-
pared with that of the diabetic control group (p<0.01).
Hypoglycemic effect of Corni Fructus
Oral glucose tolerance tests were used to determine the 
acute effect of Corni Fructus on diabetic rats. Corni Fruc-
tus supplementation improved glucose tolerance (Fig. 1). 
Plasma glucose concentration peaked at 30 minutes after 
oral glucose loading and then decreased to baseline by 60 
minutes in normal rats. However, plasma glucose concen-
trations were still higher in diabetic control rats at 120 min-
utes after glucose ingestion. In Corni Fructus-treated 
groups, blood glucose levels peaked at 30 minutes and 
promptly decreased to the fasting level by 60 minutes, and 
blood glucose levels were lower than that of the fasting lev-
The PCR cycle was 94°C for 5 minutes, then 35 cycles at 
94°C for 50 seconds, 60°C for 1 minute, and 72°C for 1 min-
ute, and finally 72°C for 10 minutes. The PCR samples 
were electrophoresed on 1% agarose gels and gel images 
were analysed after staining with ethidium bromide. RT-
PCR values are presented as the ratio of the specified gene 
signal in the selected linear amplification cycle divided by 
the β-actin signal.
Renal histological analysis
One quarter of the kidney tissues from each rat were im-
mersed in neutral buffered formalin solution, fixed with 10% 
neutral formalin phosphate buffer, dehydrated through a 
graded alcohol series, embedded in paraffin, cut into 4 µm 
sections and stained with periodic acid-schiff (PAS) stain. 
The sections were viewed with a Nikon light microscope by 
an experienced pathologist. Slides were evaluated under 
400×magnification. After five slides of each specimen were 
photographed, the cross-sectional area and glomerular radi-
us of each section were assessed. Glomerular volume (Gv) 
was calculated by the formula: Gv=4πr3/3.17 The mesangial 
expansion index was scored by quantitatively estimating 
the width of the mesangial zones in each glomerulus, and 
was expressed as a function of the total glomerular area18: 
0, normal glomeruli; 1, matrix expansion occurred in up to 
50% of the glomeruli; 2, matrix expansion occurred in 50-
75% of the glomeruli; 3, matrix expansion occurred in 75-
100% of the glomeroli. Each slide was scored by a patholo-
gist who was unaware of the experimental details.
Statistical analysis
Statistical analyses were performed using the SPSS 13.0 soft-
ware. The effects of Corni Fructus on OGTT and hypoglyce-
mia were determined using two-way ANOVA with repeated 
measures, followed by the Turkey test. Differences in antiox-
idant enzymes and renal function parameters among diabetic 
controls and groups treated with different doses of Corni 
Table 1. Body Weights (g) of Normal and Corni Fructus-Treated Diabetic Rats
Groups 0 days 10 days 20 days 30 days 40 days
Group I 233.38±5.13  264.25±7.52
†  284.13±5.74
†    301.75±10.21
†  325.63±6.55
†
Group II 233.38±4.24 225.88±4.55 217.88±4.76 210.13±4.97 207.88±5.14
Group III 235.13±5.67     235.5±3.66*  239.75±5.75
†  243.13±5.30
†  246.63±7.35
†
Group IV 232.75±6.18  247.63±4.53
†  260.25±6.20
†  271.13±5.49
†  283.38±8.26
†
Group V 231.75±6.18  251.38±5.01
†  269.13±8.63
†  284.63±6.52
†  301.13±9.29
†
SE, standard error. 
The values are means±SE of eight rats per group.
*p<0.05 vs. the diabetic control group (Group II). 
†p<0.01 vs. the diabetic control group (Group II). Antidiabetic Effects of Corni Fructus
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 695
el at 2 hours (Group IV and V). It is obvious that Corni 
Fructus administration prevented drastic increases of blood 
glucose after glucose loading, and also decreased the glu-
cose levels significantly in a concentration-dependent man-
ner. The differences between Corni Fructus-treated groups 
and the diabetic control group at 120 minutes were statisti-
cally significant.
In the forty-day glucose test, all rats were treated as above 
for 40 days, and blood glucose levels were monitored at 10 
days intervals (Fig. 2). They consistently remained at similar 
levels in both the normal and diabetic control groups during 
the experiment, i.e., from day 0 to day 40. However, signifi-
cantly lower blood glucose levels were observed in Corni 
Fructus-treated groups (p<0.05 or 0.01). Blood glucose lev-
els, however, did not return to normal levels in Corni Fruc-
tus-treated groups. Blood glucose decreased in Groups III, 
IV, and V by 20.98, 48.39 and 58.34%, respectively. These 
results indicate that Corni Fructus induced a more pro-
nounced hypoglycemic effect in the streptocotocin-induced 
diabetic rats in a dose-dependent manner.
Hypolipidemic effect of Corni Fructus
The effect of Corni Fructus treatment on serum lipids of 
tested groups is given in Table 2. The levels of TG, TC and 
LDL-C in Group II were 1.228±0.025, 2.033±0.033 and 
0.749±0.023 mM, respectively, and were significantly high-
er (p<0.05, 0.01) than those of normal rats. When diabetic 
rats were treated with Corni Fructus for 40 days, TG, TC 
and LDL-C serum levels were reduced (p<0.05, 0.01) com-
pared to diabetic control rats. The Corni Fructus-treated 
groups also had a significantly higher HDL-C level than di-
abetic control rats (p<0.05), which had HDL-C levels close 
to that of normal rats.
Change in renal function related parameters
During the study period, the levels of serum creatinine, 
urine protein and BUN in STZ-diabetic rats were signifi-
cantly higher than those of normal rats (Table 3), while 
those in STZ-diabetic rats receiving Corni Fructus treat-
ment (40 days) tended to be reduced; at the termination of 
40-day treatment, the values for serum creatinine, urine 
Table 2. Effects of Corni Fructus Treatments on Blood Lipids
Groups TG (mM ) TC (mM) LDL-C (mM) HDL-C (mM)
Group I  0.925±0.027
†    1.84±0.031
† 0.996±0.072
†   0.844±0.019*
Group II 1.228±0.025 2.033±0.033 1.284±0.060 0.749±0.023
Group III 1.195±0.024 1.951±0.030 1.234±0.055 0.796±0.017
Group IV 1.162±0.039  1.821±0.025
†  1.149±0.042
†   0.846±0.016*
Group V  1.064±0.039*  1.849±0.026
†  1.136±0.073
†   0.845±0.021*
SE, standard error.
The values are means±SE of eight rats per group. 
*p<0.05 vs. the diabetic control group (Group II). 
†p<0.01 vs. the diabetic control group (Group II). 
Fig. 1. Effects of oral glucose tolerance test on Corni Fructus-treated dia-
betic rats. The values are means±SE of eight rats per group. *p<0.05 vs. the 
diabetic control group (Group II). 
Fig. 2. Effect of Corni Fructus treatment on blood glucose levels in diabetic 
rats. The values are means±SE of eight rats per group. *p<0.05 vs. the diabet-
ic control group (Group II). 
†p<0.01 vs. the diabetic control group (Group II). 
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Influence on renal histology
In PAS-stained images of glomeruli at the end of the 40-
day treatment period (Fig. 3), there was significant glomer-
ular hypertrophy and expansion of the mesangial area in 
STZ-diabetic rats compared with normal rats. The glomeru-
lar hypertrophy and mesangial matrix accumulation in-
duced by STZ were significantly suppressed by 40 days of 
Corni Fructus treatment (Group IV and V) compared to the 
diabetic control group. Furthermore, morphometric analy-
sis indicated that the Corni Fructus treatment (Group V) 
significantly inhibited the increase of glomerular volume 
(Fig. 3F) and mesangial expansion index compared with 
vehicle treatment (Fig. 3G), indicating that the intake of 
Corni Fructus slowed down functional and pathological 
deterioration of diabetic nephropathy in these rats. 
Effect on MDA content and CAT, SOD and GSH-px  
activities
The levels of SOD, GSH-px, CAT and MDA in normal, 
protein and BUN in Groups IV and V were significantly 
lower than those of diabetic rats (p<0.01). In addition, the 
water consumption of normal rats was stable during the ex-
perimental period, but was significantly increased in diabet-
ic control rats than in normal rats. Water consumption in 
Corni Fructus-treated groups (Groups III, IV, and V) de-
creased during the experimental period. On the fortieth day, 
the water consumption of these Corni Fructus-treated 
groups was approximately half of that of the diabetic con-
trol group.
Influence on kidney hypertrophy
The mean ratio of kidney weight to body weight in STZ-in-
duced diabetic rats increased significantly compared to that 
of the normal group (p<0.01). Corni Fructus-treated diabetic 
rats (Group III) had slightly reduced renal hypertrophy at the 
termination of the 40-day treatment, and there was a marked 
reduction in the above parameters in STZ-diabetic rats after 
Corni Fructus treatment (Groups IV and V) (Table 3).
Table 3. Changes in Renal Function Parameters in Experimental Rats
Parameter Normal rats
Diabetic rats
Control rats
Corni Fructus treated
Group III Group IV GroupV
Water intake (mL/d) 35.4±4.8
† 129.6±9.4 79.8±7.3
† 63.9±6.8
† 59.6±6.4
†
Creatinine (μmol/L) 39.84±2.34
†   70.49±3.09  62.54±2.25* 60.91±2.35
† 61.12±2.49
†
Urine pro. (mg/24 hrs) 16.99±1.40
†   39.65±2.69  28.88±2.41* 25.77±2.17
† 23.58±2.67
†
BUN (mM) 14.35±1.22
†   20.44±1.96  17.52±1.25* 15.14±1.29
† 15.14±1.17
†
KW/BW( ‰)   3.25±0.13
†     4.38±0.32  4.15±0.22    3.77±0.19*   3.68±0.22
†
SE, standard error; BUN, blood urea nitrogen; KW/BW, kidney weight/body weight.   
The values are means±SE of eight rats per group.
*p<0.05 vs the diabetic control group (Group II).
†p<0.01 vs the diabetic control group (Group II). 
Fig. 3. Representative photomicrographs (original magnification, ×400) of PAS stained kidney sections. (A) Group I (B) Group II (C) Group III (D) Group IV (E) 
Group V rats (F) Glomerular volume, and (G) expansion of matrix index expressed as a quantitative estimate score. All values are means±SD. *p<0.05, com-
pared with STZ-treated group, 
†p<0.05, compared with STZ-treated group. PAS, periodic acid-schiff; STZ, streptozotocin; SD, standard deviation. 
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Expression levels of PPARγ in kidneys
The protein was isolated from one quarter of the kidney tis-
sues of treated rats and expression levels of PPARγ were de-
termined by Western blotting. PPARγ expression levels in 
normal, diabetic and Corni Fructus-treated rats are shown in 
Fig. 4. STZ-induced diabetic rats, PPARγ levels decreased 
significantly by 43.94%. Expression levels of PPARγ in 
Corni Fructus-treated diabetic rats (100, 200 and 400 mg/kg 
body mass) were higher compared with diabetic control rats 
(p<0.01), indicating that Corni Fructus treatment signifi-
cantly stimulated the expression of PPARγ in diabetic rats.
Total RNA was isolated from the kidney tissues of Groups 
I to V rats, and semi-quantitative RT-PCR was carried out 
to investigate the expression levels of PPARγ. PPARγ ex-
pression levels in normal, diabetic and Corni Fructus-treat-
ed rats are shown in Fig. 5. In STZ-induced diabetic rats, 
PPARγ levels decreased significantly by 43.3%, whereas 
the expression levels of PPARγ in Corni Fructus-treated di-
abetic rats (100, 200 and 400 mg/kg) were higher compared 
diabetic and Corni Fructus-treated rats are shown in Table 
4. In STZ-induced diabetic rats, kidney SOD, GSH-px and 
CAT levels decreased significantly by 13%, 25%, and 
33%, respectively. MDA increased by 31% in the kidney 
of diabetic rats. Corni Fructus at 100 mg/kg body mass 
did not have a significant effect on SOD, CAT and GSH-
px activities in the kidney of STZ-diabetic rats (p>0.05). 
However, activities of SOD, CAT and GSH-px in Corni 
Fructus-treated diabetic rats (200 and 400 mg/kg body 
mass) were significantly increased (p<0.05, 0.01). Further-
more, Corni Fructus at a dose of 100 mg/kg body mass 
did not significantly decrease STZ-induced increases in 
MDA level in the rat kidney. MDA levels in the kidneys of 
Groups IV and V (200 and 400 mg/kg body mass) were 
decreased significantly by 14% and 22%, respectively. 
Corni Fructus treatment, therefore, significantly blocked 
the increase of MDA and was associated with a partial ele-
vation of kidney total antioxidant ability, including SOD, 
CAT and GSH-px activities.
Table 4. Effects on the Content of Antioxidant Enzymes and MDA in Experimental Rats
Group I Group II Group III Group IV Group V
SOD (U/mg protein) 51.28±1.35
† 44.69±0.74 44.94±0.82 47.69±1.02 49.15±0.7*
GSH-px (U/mg protein) 33.05±1.09
† 24.84±0.77 24.96±0.79   28.37±0.76*   30.27±0.82*
CAT (U/mg protein)   5.35±0.09
†   3.59±0.06   4.01±0.12    4.22±0.13
†    4.27±0.11
†
MDA (nmol/mg)   9.14±0.45
† 13.21±0.48 11.54±0.49 11.33±0.38   10.28±0.39*
SOD, superoxide dismutase; GSH-px, glutathione peroxidase; CAT, catalase; MDA, malondialdehyde; SE, standard error.
The values are means±SE of eight rats per group. 
*p<0.05 vs. the diabetic control group (Group II).
†p<0.01 vs. the diabetic control group (Group II).
Fig. 4. Levels of PPARγ in kidney tissues of experimental rats. Western blot-
ting analysis shows the expression levels of PPARγ in kidney tissues. The 
values are means±SD of eight rats per group. *p<0.01 vs. the diabetic con-
trol group (Group II). PPAR, peroxisome proliferator-activated receptor; SD, 
standard deviation. 
Fig. 5. PPARγ transcription level in the kidney tissues of experimental rats.   
RT-PCR analysis shows the expression levels of PPARγ (top panel), and 
β-actin (bottom panel) in kidney tissues. The values are means±SD of eight 
rats per group; *p<0.01 vs the diabetic control group (Group II). PPAR, per-
oxisome proliferator-activated receptor; RT-PCR, reverse transcriptase poly-
merase chain reaction; SD, standard deviation. 
0 0
5
10
15
20
25
5
10
15
20
P
P
A
R
-
g
a
m
m
a
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
P
P
A
R
-
g
a
m
m
a
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
Group I Group I
PPAR
β-actin
Group II Group II Group III Group III Group IV Group IV Group V Group V
*
*
* *
*
*
*
*Dawei Gao, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 698
betic rats. Increased kidney weight and accelerated mesan-
gial expansion in the glomeruli of STZ-diabetic rats were 
alleviated by 40 days of Corni Fructus treatment. These re-
sults demonstrate that Corni Fructus has potent effects on 
the deterioration of renal expansion and hyperfiltration by 
reducing renal extra-cellular matrix accumulation in STZ-
diabetic rats, possibly leading to the amelioration or delay 
in the development of advanced diabetic renal injury.
Streptozotocin-induced diabetes is characterized by a se-
vere loss in body weight,26 which might be the result of pro-
tein wasting due to the unavailability of carbohydrate as an 
energy source.27 In our study, oral administration of Corni 
Fructus reduced the decline in body weight in diabetic rats. In 
addition, we observed significant increases in the levels of 
TC, TG and LDL-C in diabetic rats, and the 40-day Corni 
Fructus treatment not only lowered the levels of TC, TG and 
LDL-C, but also enhanced the levels of the cardioprotective 
lipid HDL-C. It is likely that the hypolipidemic effect of Cor-
ni Fructus results from the inhibition of cellular cholesterol 
and triglyceride synthesis, thus suggesting that Corni Fructus 
may be beneficial to diabetic individuals with hyperlipidemia. 
Several studies have documented that oxidative stress is 
accelerated in diabetes mellitus owing to an increase in the 
production of oxygen free radicals, lipid peroxidation and 
low-density lipoprotein.28,29 Free radicals can diffuse intra-
celluarly and result in mitochondrial enzyme damage and 
DNA breaks, all of which impair cellular function and con-
tribute to the pathophysiology of diabetes.30,31 Oxygen free 
radicals exert their cytotoxic effects on membrane phospho-
lipids, resulting in the formation of MDA. As a product of 
lipid peroxidation, the levels of MDA reflect the degree of 
oxidation in the body. As components of the free radical 
scavenging system, SOD, CAT and GSH-px exist in all ox-
ygen-metabolizing cells, prevent damage to cells by free 
radicals and provide a repair mechanism for oxidized mem-
brane components. In the present study, diabetic nephropa-
thy was significantly improved in rats receiving Corni Fruc-
tus. Furthermore, we observed a significant increase in SOD, 
CAT and GSH-px activities in Corni Fructus-treated diabetic 
groups compared with the untreated diabetic control group, 
and the treatment of Corni Fructus also decreased the level 
of MDA in the diabetic rats. The increases in antioxidases 
provide effective protection from oxidative damage. 
It is worth noting that chronic diabetic nephropathy re-
duces the PPARγ mRNA levels in glomeruli.32 PPARγ is a 
master transcriptional regulator in lipid and glucose metab-
olism, and induces lipogenic gene transcription and dipo-
with diabetic control rats (p<0.01). These results also show 
that the Corni Fructus treatment significantly stimulated 
the expression of PPARγ in diabetic rats.
DISCUSSION
Diabetic nephropathy is the most serious complication in dia-
betes mellitus, and one of the most important microvascular 
complications of diabetic patients. It has been suggested to 
result from interactions between metabolic and hemodynam-
ic factors involved with hyperglycemia. Currently available 
drugs for diabetes have a number of limitations, such as ad-
verse effects and high rates of secondary failure.19,20 This situ-
ation has led to the search for alternative therapies from natu-
ral products that have low or no side effects and multi-target 
actions.21 Even the WHO expert committee on diabetes has 
recommended that this area warrants further attention.22 In 
the present study, the main compound of Corni Fructus was 
shown to be ursolic acid after ultrasonic extraction and purifi-
cation using macroporous resins, and pharmacological inter-
vention with Corni Fructus (200 and 400 mg/kg body mass) 
significantly relieved hyperglycemia, hyperlipidemia, and di-
abetic nephropathy in STZ-induced diabetic rats. OGTT data 
indicated that the postprandial blood glucose was markedly 
decreased after treatment with Corni Fructus suggesting that 
Corni Fructus can improve the sensitivity or stimulate secre-
tion of insulin in the STZ-induced diabetic rats.  Neverthe-
less, further research is needed. 
Diabetes is a metabolic disorder affecting carbohydrate, 
fat and protein metabolism, and is complicated by multior-
gan deterioration in the latter stages of the illness. Urinary 
albumin excretion has been shown to be a good clinical pre-
dictor of renal lesions in diabetic nephropathy.23,24 The in-
crease in urinary albumin excretion, one of the most marked 
renal pathological findings in diabetic nephropathy results 
from mesangial expansion, due to pathological accumula-
tion of extra-cellular matrix components.25 In the present 
study, increase in urinary albumin concentration correspond-
ing to the hyperglycemia was more pronounced following 
induction of diabetes. In addition, levels of serum creatinine 
and BUN, which are generally considered as markers of re-
nal function, were higher in STZ-diabetic rats than in nor-
mal rats, indicating the presence of diabetic nephropathy 
with renal hyperfiltration. Forty-day treatment with Corni 
Fructus attenuated albuminuria and ameliorated the loss of 
renal function and glomerular hyperfiltration in STZ-dia-Antidiabetic Effects of Corni Fructus
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cyte differentiation.33-35 Also, many animal and clinical ex-
periments demonstrated that upregulation or activation of 
PPARγ can normalize lipid and glucose metabolism disor-
ders, enhance insulin sensitivity of peripheral organs by lipo-
protein lipase hydrolyzing TG, and deliver fatty acids to the 
tissue for storage or oxidation.36,37 Moreover, rosiglitazone 
has been shown in a recent study to prevent the development 
of diabetic nephropathy by reducing podocyte loss, downreg-
ulating the expression of glomerular fibronectin and inhibit-
ing ROS accumulation in the glomerules of diabetic mice 
with nephropathy,38 and PPARγ agonists have a protective 
role against oxidative stress.39 The effects of PPARγ are me-
diated by the modulation of ROS generation and activation 
of redox-sensitive transcription factor nuclear factor-kB and 
hypoxia inducible factor (HIF-1a) in allergic airway disease 
of mice.40 However, the effects of PPARγ on antioxidative 
stress in STZ-induced diabetic rats with hyperlipidemia have 
not yet been clarified. In the present study, glucose and lipid 
in the plasma were normalized by activating PPARγ in Corni 
Fructus-treated diabetic rats, showing that activation of 
PPARγ modulated diabetes-induced kidney damage. Corni 
Fructus also increased antioxidant enzyme activities in kid-
ney tissues and reduced oxidative damage and glomerulo-
sclerosis through upregulation PPARγ expression. Therefore, 
Corni Fructus may be a PPARγ agonist to ameliorate abnor-
mal lipid and glucose metabolism.
In conclusion, our present study reveals that Corni Fruc-
tus has beneficial effects inimproving blood glucose and 
lipid levels in diabetic rats, and prevents diabetic nephropa-
thy. This study provides experimental evidence that Corni 
Fructus may be a potential therapeutic agent for hypergly-
cemia that is associated with diabetic complications includ-
ing diabetic nephropathy. 
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